Dipyridamole
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Dipyridamole: Evidence Pack Incomplete — Repurposing Evaluation Cannot Proceed
One-Sentence Summary
Dipyridamole (DrugBank: DB00975) is a cardiovascular agent with established antiplatelet and vasodilatory properties, with broad clinical use in stroke prevention and cardiac stress imaging. However, the current Evidence Pack contains no TxGNN predicted new indications, and key data fields — including mechanism of action, safety warnings, and contraindications — are absent, making a complete repurposing evaluation impossible at this stage. No further evidence review can be conducted until the pipeline gaps identified below are resolved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | No TxGNN predictions present |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack contains no TxGNN predicted indications, and all critical upstream data — mechanism of action, regulatory safety warnings, and drug–drug interactions — are unresolved. There is no evidence base on which to build a repurposing evaluation.
To proceed, the following is needed:
- Re-run TxGNN prediction for Dipyridamole (DB00975) to generate repurposing candidate indications with confidence scores
- Retrieve mechanism of action from DrugBank API (DG002 — High severity)
- Parse TFDA package insert to extract warnings and contraindications (DG001 — Blocking severity); the query log confirms a PDF was retrieved on 2026-03-29 but content was not ingested into the Evidence Pack
- Query drug–drug interaction database — current result status is
not_found; confirm whether this reflects a true absence of known interactions or a query failure - Once regulatory data is available, verify whether Dipyridamole has any market authorisation in target markets outside New Zealand
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.